Corcept Therapeutics

11 hours ago · defenseworld.net

Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) insider Roberto Vieira sold 296 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $100.82, for a total transaction of $29,842.72. Following the transaction, the insider directly owned 3,946 shares in the company, valued at

3 days ago · businesswire.com

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit.

5 days ago · zacks.com

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.

5 days ago · fxempire.com

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.

13 days ago · seekingalpha.com

Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.

24 days ago · zacks.com

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

1 month ago · seekingalpha.com

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.

1 month ago · finbold.com

President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.

2 months ago · zacks.com

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

2 months ago · fxempire.com

CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing's syndrome.